Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Mathias Lutz, Arik B. Schulze, Elisabeth Rebber, Stefanie Wiebe, Tarek Zoubi, Oliver M. Grauer, Torsten Keßler, Andrea Kerkhoff, Georg Lenz, Wolfgang E. Berdel
Cancer Res Treat. 2017;49(2):548-552.   Published online 2016 Jul 12     DOI: https://doi.org/10.4143/crt.2016.110
Citations to this article as recorded by Crossref logo
The Use of Antimalarial Drugs against Viral Infection
Sarah D’Alessandro, Diletta Scaccabarozzi, Lucia Signorini, Federica Perego, Denise P. Ilboudo, Pasquale Ferrante, Serena Delbue
Microorganisms.2020; 8(1): 85.     CrossRef
Ibrutinib-induced polyneuropathy: A case report
Pınar Cömert, Murat Albayrak, Abdulkerim Yıldız, Osman Şahin, Hacer Berna Öztürk, Merih Reis Aras
Journal of Oncology Pharmacy Practice.2020; 26(6): 1501.     CrossRef
JC Polyomavirus Infection Potentiated by Biologics
Ashrit Multani, Dora Y. Ho
Infectious Disease Clinics of North America.2020; 34(2): 359.     CrossRef
Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
Phil‐Robin Tepasse, Wali Hafezi, Mathias Lutz, Joachim Kühn, Christian Wilms, Rainer Wiewrodt, Jan Sackarnd, Martin Keller, Hartmut H. Schmidt, Richard Vollenberg
British Journal of Haematology.2020; 190(2): 185.     CrossRef
Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin’s lymphoma
Thai Dang, Samir Macwan, Constantin A Dasanu
Journal of Oncology Pharmacy Practice.2020; : 107815522097679.     CrossRef
Progressive multifocal leukoencephalopathy in a patient with relapsed chronic lymphocytic leukemia treated with Ibrutinib
Larissa Lane Cardoso Teixeira, Viviane Regina Hernandez Nunes, Guilherme Fleury Perini, Carolina Cristina Pellegrino Feres, Danielle Ovigli, Nelson Hamerschlak
Hematology, Transfusion and Cell Therapy.2020;[Epub]     CrossRef
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—A single institution experience and a review of literature
Hira Shaikh, Ahmed Khattab, Muhammad S Faisal, Abhishek Chilkulwar, Mary Albrethsen, Santhosh Sadashiv, Salman Fazal
Journal of Oncology Pharmacy Practice.2019; 25(5): 1265.     CrossRef
Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
Georg Maschmeyer, Julien De Greef, Sibylle C. Mellinghoff, Annamaria Nosari, Anne Thiebaut-Bertrand, Anne Bergeron, Tomas Franquet, Nicole M. A. Blijlevens, Johan A. Maertens
Leukemia.2019; 33(4): 844.     CrossRef
Neurological complications of new chemotherapy agents
Alicia M Zukas, David Schiff
Neuro-Oncology.2018; 20(1): 24.     CrossRef
Neuro-ophthalmic side effects of molecularly targeted cancer drugs
M T Bhatti, A K S Salama
Eye.2018; 32(2): 287.     CrossRef
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi, J.M. Aguado
Clinical Microbiology and Infection.2018; 24: S53.     CrossRef
Une hépatite inhabituelle chez un patient traité par obinutuzumab et ibrutinib
S. Giorgiutti, M.P. Ledoux, E. Toussaint, Q. Maestraggi, C. Besch, M. Solis, R. Herbrecht, L.M. Fornecker
La Revue de Médecine Interne.2018; 39: A202.     CrossRef
Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
Ensi Voshtina, Huiya Huang, Renju Raj, Ehab Atallah
Case Reports in Hematology.2018; 2018: 1.     CrossRef
Cryptococcus neoformansempyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature
Christopher David Swan, Thomas Gottlieb
BMJ Case Reports.2018; : bcr-2018-224786.     CrossRef
Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency
S. A. Misbah
Clinical & Experimental Immunology.2017; 188(3): 342.     CrossRef
T cell therapies for human polyomavirus diseases
Sarah I. Davies, Pawel Muranski
Cytotherapy.2017; 19(11): 1302.     CrossRef
Fludarabine/ibrutinib/rituximab
Reactions Weekly.2017; 1657(1): 200.     CrossRef
The safety profile of monoclonal antibodies for chronic lymphocytic leukemia
Anna Korycka-Wołowiec, Dariusz Wołowiec, Tadeusz Robak
Expert Opinion on Drug Safety.2016; : 1.     CrossRef